- Respiratory failure: SpO₂ <90% on room air or pO₂ <60 mmHg
- Septic shock: requiring vasopressors or lactate >4 mmol/L
- Multilobar involvement: high risk for ARDS
Community‑Acquired Pneumonia (CAP)
Must-Not-Miss / Red Flags
Definition & Core Concept
Community‑acquired pneumonia (CAP) is an acute infection of the lung parenchyma acquired outside the hospital setting, causing cough, fever, pleuritic chest pain, and alveolar consolidation on imaging.
Epidemiology & Risk Factors
- Annual incidence: 5‑11 per 1,000 adults
- Leading cause of infectious death in developed countries
- Risk factors: age >65, COPD, heart failure, DM, immunocompromised state
Pathophysiology (Rule of 3)
- Microaspiration or inhalation of pathogen → colonization of alveoli
- Alveolar macrophages overwhelmed → inflammatory response → neutrophil recruitment
- Alveolar exudate and consolidation → impaired gas exchange → hypoxemia
Clinical Presentation
- Productive cough with purulent sputum, fever, pleuritic chest pain, dyspnea
- Examination: crackles, bronchial breath sounds, egophony, increased tactile fremitus
- Atypical presentation in elderly: confusion, falls, absence of fever
Diagnostic Workup
Chest X‑ray: lobar consolidation, infiltrate. Labs: CBC, BMP, blood cultures x2. Sputum culture: if severe CAP or risk of MRSA/Pseudomonas. Legionella and pneumococcal urinary antigen: for severe CAP. Procalcitonin: can guide antibiotic duration.
Management Protocol
- Risk stratification: CURB‑65 or PORT score; treat as outpatient (score 0‑1), inpatient (score 2), or ICU (score ≥3)
- Empiric antibiotics: Ceftriaxone 1‑2 g IV + Azithromycin 500 mg IV/PO for ward patients; add Vancomycin for ICU/severe CAP
- Oxygen therapy: target SpO₂ ≥92%
- IV fluids for dehydration
- Duration: 5‑7 days for most; longer for Legionella or complicated cases
Complications & Prognosis
- Parapneumonic effusion/empyema
- Lung abscess
- ARDS and respiratory failure
- Sepsis and multi‑organ failure
ICU Criteria
ICU admission if: mechanical ventilation required, septic shock, or ≥3 CURB‑65 criteria.
Clinical Vignette
Pearls & Pitfalls
- “Walking pneumonia” (Mycoplasma pneumoniae) presents with dry cough, headache, and minimal chest findings – macrolides are first‑line.
- The pneumococcal vaccine reduces severity of CAP but does not prevent all cases.
Discharge & Follow-Up
Repeat CXR in 6‑8 weeks to confirm resolution and rule out underlying malignancy. Administer pneumococcal vaccine before discharge if not previously immunized.
Literature & Guidelines
ATS/IDSA 2024 Guidelines on CAP in Adults. PMID: 38593201.